Key Takeaways:
A class-action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) after the company’s stock price plunged 18.56% following the disclosure of a U.S. Department of Justice investigation into its share trading.
"The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests in the outcome," said Joseph E. Levi of Levi & Korsinsky, one of several firms that has announced actions. "In the Regencell case, where a DOJ subpoena into share trading triggered an 18.56% stock decline, investors with significant losses should evaluate whether lead plaintiff appointment serves their interests."
The lawsuit covers investors who acquired Regencell securities between October 28, 2024, and October 31, 2025. The action follows a November 3, 2025, session where RGC shares fell $3.09 to close at $13.56. The lead plaintiff motion deadline has been set for June 23, 2026.
The legal action centers on allegations that Regencell and its top officers made false and misleading statements, failing to disclose the company’s vulnerability to market manipulation. With just twelve employees, no revenue, and minimal R&D spending, the company’s market value briefly soared to an estimated $14 billion, a valuation disconnected from its business fundamentals.
The lawsuit filings detail an extraordinary period of volatility that appears to have attracted regulatory scrutiny. From early 2025, Regencell's stock, which had been trading for under 30 cents, began a meteoric ascent, peaking at $78.00 per share on June 17, 2025. This represented a 48,650% increase from the start of the class period.
The complaint alleges that this rise had no basis in the company's public disclosures or underlying business, which is focused on developing traditional Chinese medicine to treat neurocognitive disorders. The company itself admitted in a filing that its "stock price has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of our company." The truth began to emerge on October 31, 2025, when Regencell disclosed it had received a subpoena from the DOJ, prompting the sharp sell-off.
The lawsuit specifically names founder and CEO Yat-Gai Au and Financial Controller Michelle Chan as individual defendants, citing their roles as "controlling persons" under Section 20(a) of the Securities Exchange Act. As of June 2025, Au held a commanding 88.6% of the company's shares.
The complaint argues that both executives signed Sarbanes-Oxley certifications attesting to the accuracy of SEC filings. These filings are now alleged to have been misleading by omitting the risks of market manipulation and potential regulatory action. The plaintiffs contend that the defendants, particularly Au with his massive personal stake, had a motive to conceal adverse facts that could destabilize the soaring share price.
For Regencell investors, the lawsuit means a potential path to recovering losses, but the immediate focus is the June 23, 2026, deadline to file for lead plaintiff status. This role allows an investor to direct the litigation but does not increase their individual share of any potential recovery.
The legal proceedings will likely scrutinize the vast disconnect between Regencell's market capitalization and its operational reality. The case highlights the risks of extreme volatility and the legal accountability corporate officers face for their public statements. Investors will be watching for the court's appointment of a lead plaintiff after the June deadline.
This article is for informational purposes only and does not constitute investment advice.
